The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A phase II trial of the Sarah Cannon Research Institute (SCRI).
John H. Barton
No relevant relationships to disclose
Eric Raefsky
No relevant relationships to disclose
William N. Harwin
No relevant relationships to disclose
Alejandro A. Inclan
No relevant relationships to disclose
Gerald Miletello
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Denise Aysel Yardley
No relevant relationships to disclose